TScan Therapeutics (TCRX) has priced its IPO of ~6.7M shares of common stock at $15.00/share, for gross proceeds of $100M.
The company initially filed to offer 6.25M shares at a price range of $15-$17.
- TScan is a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies (TCR-T) for the treatment of patients with cancer.
- The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation.
- TCRX is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
- The company plans to submit IND applications for each of TSC-100 and TSC-101 with the FDA in Q4 2021.
No comments:
Post a Comment